/KALA
KALA Stock - KALA BIO, Inc.
Healthcare|BiotechnologyNASDAQ
$0.62+7.55%
+$0.04 (+7.55%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+141.0%upside
Target: $1.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KALA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.62 – $0.63
TARGET (TP)$1.50
STOP LOSS$0.57
RISK/REWARD1:16.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.51
52W High$20.60
52W Low$0.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $3.89M | $11.24M | $6.36M |
| Gross Profit | $-259,000 | $-303,000 | $1.33M | $7.14M | $3.19M |
| Gross Margin | N/A | N/A | 34.2% | 63.5% | 50.1% |
| Operating Income | $-40,983,000 | $-39,153,000 | $-81,356,000 | $-109,433,000 | $-96,231,000 |
| Net Income | $-38,511,000 | $-42,199,000 | $-44,822,000 | $-142,605,000 | $-104,327,000 |
| Net Margin | N/A | N/A | -1151.6% | -1268.7% | -1639.8% |
| EPS | $-6.98 | $-17.35 | $-29.48 | $-109.35 | $-99.59 |
Company Overview
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
3
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$15
Average Target
↑ 2230.1% Upside
Now
$2
Low
$15
Average
$30
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 30th 2025 | Mizuho | Downgrade | Neutral | $1.5 |
| September 29th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| September 29th 2025 | Ladenburg Thalmann | Downgrade | Neutral | - |
| September 8th 2025 | Mizuho | Initiation | Outperform | $30 |
| July 11th 2025 | Ladenburg Thalmann | Initiation | Buy | $12 |
Earnings History & Surprises
KALABeat Rate
53%
Last 19 quarters
Avg Surprise
-5.0%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-1.07
Q4 2025
EPS Surprise History
Q1 24
+12.2%
$-3.18vs$-3.62
Q2 24
-45.3%
$-4.20vs$-2.89
Q3 24
+28.3%
$-3.16vs$-4.41
Q4 24
+20.6%
$-1.93vs$-2.43
Q1 25
+23.7%
$-1.74vs$-2.28
Q2 25
+30.5%
$-1.41vs$-2.03
Q3 25
+6.0%
$-1.71vs$-1.82
Q4 25
-5.9%
$-1.07vs$-1.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | $-1.01 | $-1.07 | -5.9% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-1.82 | $-1.71 | +6.0% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-2.03 | $-1.41 | +30.5% | ✓ BEAT |
Q1 2025 | Mar 31, 2025 | $-2.28 | $-1.74 | +23.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-2.43 | $-1.93 | +20.6% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-4.41 | $-3.16 | +28.3% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-2.89 | $-4.20 | -45.3% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-3.62 | $-3.18 | +12.2% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-2.15 | $-3.41 | -58.6% | ✗ MISS |
Q3 2023 | Aug 4, 2023 | $-3.19 | $-4.36 | -36.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-5.10 | $-6.99 | -37.1% | ✗ MISS |
Q1 2023 | Mar 3, 2023 | $-6.56 | $-7.97 | -21.5% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $10.75 | $19.25 | +79.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-22.00 | $-19.00 | +13.6% | ✓ BEAT |
Q2 2022 | May 16, 2022 | $-18.00 | $-22.50 | -25.0% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-21.50 | $-34.00 | -58.1% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-22.50 | $-21.50 | +4.4% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-22.00 | $-28.50 | -29.5% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-25.50 | $-24.50 | +3.9% | ✓ BEAT |
Latest News
KALA BIO Shares Resume Trade
➖ NeutralBenzinga•Dec 4, 2025, 03:51 PM
KALA BIO Shares Halted On Circuit Breaker To The Downside, Stock Now Up 14.59%
➖ NeutralBenzinga•Dec 4, 2025, 03:48 PM
KALA BIO Enters Announces $10M Registered Direct Offering Of 10M Shares At $1/Share To Repay Debt And Fund Corporate Purposes
➖ NeutralBenzinga•Dec 4, 2025, 03:47 PM
KALA BIO shares are trading higher after the company announced it secured a $6 million securities purchase agreement. The company appointed David Lazar as CEO and Chairman of the Board.
📈 PositiveBenzinga•Dec 1, 2025, 02:11 PM
KALA BIO Signs $6M Securities Purchase Agreement And Names David E Lazar Chief Executive Officer
📈 PositiveBenzinga•Dec 1, 2025, 12:05 PM
Kala Bio Announces On Nov 21,2025 Board Terminated Without Cause The Employment Of CFO Mary Reumuth; Appointed David Lazar As CEO; Board Appointed David Lazar As Principal Financial Officer Of Company
📉 NegativeBenzinga•Nov 25, 2025, 09:31 PM•Also:
Kala Bio Q3 EPS $(1.07) Beats $(1.45) Estimate
📈 PositiveBenzinga•Nov 19, 2025, 03:16 PM
KALA BIO Received Nasdaq Deficiency Letter
📉 NegativeBenzinga•Nov 12, 2025, 09:10 PM
KALA BIO Terminates CEO Todd Bazemore Without Cause; Oxford To Foreclose On All KALA BIO's Remaining Assets; Co Terminates All Remaining Employees For Foreclosure; Co Owes Oxford About $9.6M
📉 NegativeBenzinga•Oct 20, 2025, 12:15 PM
On Sep 29, Kala Bio Receives Notice Of Event Of Default From Oxford Finance; Total Obligations Declared Payable Is $29.1M
📉 NegativeBenzinga•Oct 1, 2025, 01:36 PM
Kala Bio shares are trading lower after its Phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect recently failed to meet the primary endpoint.
📉 NegativeBenzinga•Sep 30, 2025, 07:21 PM
Kala Bio shares are trading lower after its Phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect failed to meet the primary endpoint.
📉 NegativeBenzinga•Sep 29, 2025, 04:07 PM
KALA BIO Shares Resume Trade
➖ NeutralBenzinga•Sep 29, 2025, 03:03 PM
KALA BIO Shares Halted On Circuit Breaker To The Downside, Stock Now Down -88.82%
📉 NegativeBenzinga•Sep 29, 2025, 02:58 PM
KALA BIO Shares Halted, Stock Now Down -87.66%
📉 NegativeBenzinga•Sep 29, 2025, 02:53 PM
KALA BIO Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Sep 29, 2025, 02:52 PM
KALA BIO plunges 92% after phase 2 failure of eye condition drug
📉 NegativeSeeking Alpha•Sep 29, 2025, 12:56 PM•Also:
KALA BIO Shares Halted On Code News Pending
➖ NeutralBenzinga•Sep 29, 2025, 12:14 PM
KALA BIO CHASE Phase 2b Clinical Trial Of KPI-012 for Persistent Corneal Epithelial Defect Did Not Meet Primary Endpoint
📉 NegativeBenzinga•Sep 29, 2025, 12:02 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 29, 2025, 11:55 AM
Frequently Asked Questions about KALA
What is KALA's current stock price?
KALA BIO, Inc. (KALA) is currently trading at $0.62 per share. The stock has moved +7.55% today.
What is the analyst price target for KALA?
The average analyst price target for KALA is $1.50, based on 1 analyst.
What sector is KALA BIO, Inc. in?
KALA BIO, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KALA's market cap?
KALA BIO, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does KALA pay dividends?
No, KALA BIO, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABP
Abpro Corporation
$5.06
Mkt Cap: $0.0B
AIM
AIM ImmunoTech Inc.
$1.42
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
IBO
Impact BioMedical Inc.
$0.65
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
OGEN
Oragenics, Inc.
$0.88
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
XTLB
XTL Biopharmaceuticals Ltd.
$0.82
Mkt Cap: $0.0B
Explore stocks similar to KALA for comparison